Start the conversation
Since launching Private Briefing two years ago, we've profited from several biotech buyouts - including the double-your-money deals for Astex Pharmaceuticals Inc. and Trius Therapeutics Inc.
But this time around we're going for the gold by recommending a biotech that's been a buyer, not a seller. And an unwarranted steep sell-off late last week has the stock trading at a bargain-basement price, says Radical Technology Profits Editor Michael Robinson, our resident technology guru.
"I have to tell you, Bill, for some time now, I've had my eye on Jazz Pharmaceuticals PLC (NasdaqGS: JAZZ), an Ireland-based mid-cap biotech that's been busy on the acquisitions circuit. It's buying promising drug compounds from peer companies. And it's buying rivals outright. It's turned out to be an excellent strategy for Jazz. And last week's sell-off gives us a chance to get into this biotech at a very good price level. I think this stock will do nicely going forward."
This is premium content for Private Briefing subscribers only.